Group 1 - The core viewpoint of the article highlights a rebound in the innovative drug sector, with the Sci-Tech Innovation Drug ETF (589720) rising nearly 2% due to increased capital inflow during the recent pullback period, totaling over 270 million yuan in net inflows over the past 10 days [1] - China Galaxy Securities indicates that the pharmaceutical sector has undergone a significant valuation adjustment and is now showing a notable structural recovery trend, with expectations that the innovative drug business development (BD) will continue in the second half of the year [1] - The global trend of interest rate cuts by major central banks is anticipated to further enhance the valuation of the innovative drug sector [1] Group 2 - The Sci-Tech Innovation Drug ETF focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking an index that aggregates 30 representative high-quality companies, primarily in high-growth biotech [1] - The product features a 20% limit on daily price fluctuations, making it more aligned with the volatility of the sector [1]
创新药延续反弹，科创创新药ETF（589720）涨近2%，20cm涨跌幅限制弹性更大
Sou Hu Cai Jing·2025-11-13 01:55